Compare Adaptive Biotechnologies Corp (ADPT) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Vanguard Value Index Fund ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.89 (market cap $3.33B), while Vanguard Value Index Fund ETF trades at $218.03. The key difference: Vanguard Value Index Fund ETF is trading nearer its 52-week high, Adaptive Biotechnologies Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | VTV | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $220.51 |
52-Week Low | $10.24 | $175.51 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
VTV trades at $219.57 with a slight 0.18% daily gain, showing strong 2026 performance with a 16% year-to-date return. Technical indicators signal bullish momentum with moving averages strongly positive, while oscillators remain neutral. The ETF benefits from market rotation away from tech stocks toward value investments, with recent news highlighting its defensive positioning amid Fed policy uncertainty and AI bubble concerns.
VTV offers exposure to large-cap value stocks with minimal tech concentration, providing diversification benefits as markets shift from growth to value. Key risks include Fed rate hike sensitivity and macroeconomic volatility, though the ETF's low 0.03% expense ratio and value focus position it well for continued rotation trends. Analyst sentiment is mixed with some caution about limited upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
